The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective, noninterventional study of vinflunine treatment in advanced urothelial cell carcinoma (UCC) in routine clinical practice.
Margitta Retz
No relevant relationships to disclose
Patrick De Geeter
No relevant relationships to disclose
Peter J. Goebell
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Ullrich Matz
No relevant relationships to disclose
Wito de Schultz
No relevant relationships to disclose
Axel Hegele
Honoraria - Amgen; Novartis; Pierre Fabre Medicament